Aura Biosciences continued advancing its clinical pipeline in Q2 2025, particularly in ocular and urologic oncology. The company increased R&D spending to support Phase 3 and Phase 1b/2 trials, resulting in a wider net loss, but remained well-capitalized through 2027.

Aura Biosciences started 2025 with strong momentum, advancing both its ocular and urologic oncology programs. The company enrolled the first patient in its multi-dose Phase 1b/2 trial for NMIBC and expects initial data by year-end 2025. The global Phase 3 CoMpass trial for early-stage choroidal melanoma continues to advance, with enrollment potentially completing by the end of 2025. The company reported a net loss of $27.483 million for the quarter.

Aura Biosciences posted a Q4 2024 net loss of $25.8 million, with no reported revenue. The company continued investing in clinical trials and manufacturing for its lead candidate bel-sar, resulting in higher R&D and G&A expenses. Cash and marketable securities totaled $151.1 million, expected to fund operations into the second half of 2026.

Aura Biosciences reported positive Phase 2 end-of-study data with Bel-sar in early-stage choroidal melanoma and the ongoing Phase 3 CoMpass trial recently received authorization to start enrolling patients in Europe. Multiple clinical complete responses were observed with a single low dose of Bel-sar in the ongoing Phase 1 trial in non-muscle invasive bladder cancer. The company's strong cash position is expected to support operations into 2H 2026.

Aura Biosciences reported its Q2 2024 financial results, highlighting progress across its clinical programs, especially in the bladder cancer clinical trial. The company anticipates presenting early NMIBC data in October 2024. With a strong cash position, Aura believes it can fund operations into the second half of 2026.

Aura Biosciences reported a net loss of $19.7 million for the first quarter of 2024. As of March 31, 2024, the company's cash and cash equivalents and marketable securities totaled $202.9 million, which is expected to fund operations into the second half of 2026. Enrollment continues in the global Phase 3 CoMpass trial for choroidal melanoma, and early Phase 1 data from the bladder cancer trial is expected mid-2024.

Aura Biosciences reported increased research and development expenses and general and administrative expenses for the fourth quarter of 2023, leading to a higher net loss compared to the same period in 2022. The company's cash and cash equivalents totaled $226.2 million as of December 31, 2023, sufficient to fund operations into the second half of 2026.

Aura Biosciences reported progress across its portfolio, highlighted by the FDA agreement under the SPA for the CoMpass Phase 3 clinical trial and positive clinical efficacy updates of Bel-sar for early-stage choroidal melanoma. The company raised gross proceeds of $99.0 million in an underwritten public offering, strengthening its financial position to execute its pipeline.

Aura Biosciences reported its Q2 2023 financial results, highlighting ongoing global Phase 3 trial start-up activities and key leadership appointments. The company's cash and cash equivalents totaled $162.0 million, expected to fund operations into the second half of 2025. The first patient is expected to be dosed in the second half of 2023

Aura Biosciences reported its Q1 2023 financial results, highlighting FDA guidance supporting their global Phase 3 trial and the completion of enrollment in their Phase 2 trial. The company's cash and cash equivalents totaled $173.5 million, expected to fund operations into 2025.

Aura Biosciences reported a net loss of $16.6 million for the fourth quarter of 2022. The company's cash and cash equivalents and marketable securities totaled $188.8 million as of December 31, 2022, which is expected to fund operations into 2025. The FDA granted Fast Track Designation for Belzupacap Sarotalocan for the treatment of Choroidal Metastasis.

Aura Biosciences reported a net loss of $15.9 million for the third quarter of 2022. The company's cash and cash equivalents totaled $111.5 million as of September 30, 2022, which is expected to fund operations into 2024. The company finalized the global Phase 3 design in alignment with regulatory agencies and selected suprachoroidal route of administration to evaluate the efficacy and safety of bel-sar in early-stage CM. Aura dosed the first patient in a Phase 1 clinical trial of bel-sar for the treatment of non-muscle invasive bladder cancer (NMIBC).

Aura Biosciences reported second quarter financial results, highlighting the progress in advancing belzupacap sarotalocan's clinical development, including plans to dose the first patient in the Phase 1 trial for NMIBC in Q3 2022 and initiate a pivotal trial in early-stage choroidal melanoma in Q4 2022.

Aura Biosciences reported its first quarter 2022 financial results, highlighting ongoing progress of AU-011 and preparations for pivotal trials in choroidal melanoma, a Phase 1 trial in non-muscle invasive bladder cancer, and submission of an IND for choroidal metastases.

Aura Biosciences reported a net loss of $8.8 million for the third quarter of 2021. The company's cash and cash equivalents totaled $81.8 million as of September 30, 2021, and believes its current resources are sufficient to fund operations into 2024.